<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460303</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1136</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101136</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to support the end-of-shelf life specification (2.5 × 10<sup>10</sup> virus particles [vp]) for the standard Ad26.COV2.S dose (5 × 10<sup>10</sup> vp).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind Phase 3 study evaluated immunogenicity, reactogenicity, and safety of several Ad26.COV2.S dose levels (range 1.25 to 9 × 10<sup>10</sup> vp) in 1593 adults between June 2021 and July 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Spike-binding antibody responses 28 days post-dose 1 were non-inferior for the 9 × 10<sup>10</sup> vp, but not the 2.5 × 10<sup>10</sup> vp group when compared with the standard dose. Non-inferiority was demonstrated in terms of spike-binding antibody responses 14 days post-dose 2 for each dose level, including the lowest dose level of 1.25 × 10<sup>10</sup> vp, compared to 28 days after one dose and 14 days after two doses of the standard dose. Spike-binding antibody levels correlated well with virus neutralizing titers. There was no impact of pre-existing Ad26.COV2.S neutralizing titers on immunogenicity at any dose level. All dose levels were well tolerated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study highlights the challenges associated with conducting clinical studies in a rapidly evolving environment and underscores the importance of platform data that can guide initial vaccine specifications such as shelf life during accelerated vaccine development. The present study supports the end-of-shelf life specifications for the approved Ad26.COV2.S dose, and could provide useful information in future vaccine developments using adenovirus vector vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rezelj</LastName><ForeName>Veronica V</ForeName><Initials>VV</Initials><Identifier Source="ORCID">0000-0003-1571-8325</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paddenburg</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vimef Holding B.V., 3311 GE Dordrech, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diegbe</LastName><ForeName>Marie Enajite</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nangosyah</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cytel Global Headquarters, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisinger</LastName><ForeName>Emil C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Rostock University Medical Center, 18057 Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Weihong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Cytel Global Headquarters, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truyers</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheper</LastName><ForeName>Gert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2316-756X</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Gars</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendriks</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyf</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douoguih</LastName><ForeName>Macaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuitemaker</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention, 2301 CN Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Guiñazú</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>not applicable</GrantID><Agency>Janssen Vaccines &amp; Prevention B.V</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ad26.COV2.S</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">spike-binding antibodies</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Veronica V. Rezelj, Marie Enajite Diegbe, Carla Truyers, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker, and Javier Ruiz-Guiñazú are or were employees of Johnson &amp; Johnson, LLC at the time of the study. Frank Struyf, Javier Ruiz-Guiñazú, Carla Truyers, Gert Scheper, Macaya Douoguih, Hanneke Schuitemaker hold stock/stock options. Frank Struyf and Javier Ruiz-Guiñazú hold stock/stock/options in GSK as renumeration for past employment. Frank Struyf is currently an employee of GSK. Fred Paddenburg declares no conflicts of interest. Weihong Hu declares no conflicts of interest. Julius Nangosyah declares no conflicts of interest. Emil C. Reisinger received grants from Johnson &amp; Johnson, LLC for the conduct of this study. The funder designed the study, conducted the analysis, and was involved in interpretation of the data; in the writing of the manuscript; and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460303</ArticleId><ArticleId IdType="pmc">PMC11511116</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101136</ArticleId><ArticleId IdType="pii">vaccines12101136</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Medicines Agency  Jcovden (Previously COVID-19 Vaccine Janssen) Summary of Product Characteristics.  [(accessed on 16 October 2023)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Van Dromme I., Spiessens B., et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med. 2022;386:847–860. doi: 10.1056/NEJMoa2117608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117608</ArticleId><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasandro M., Choudhury D., Huynh-Ba K., Kochling J., Latoz C., Larkin L., McCaig L., Subbarao N., Wu Y., Zhang Y. Meeting report: Vaccine stability considerations to enable rapid development and deployment. AAPS Open. 2021;7:6. doi: 10.1186/s41120-021-00042-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41120-021-00042-1</ArticleId><ArticleId IdType="pmc">PMC8632204</ArticleId><ArticleId IdType="pubmed">34869830</ArticleId></ArticleIdList></Reference><Reference><Citation>MMR-162 Study Group Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: A phase III, randomized study. Hum. Vaccin. Immunother. 2018;14:2921–2931. doi: 10.1080/21645515.2018.1502527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1502527</ArticleId><ArticleId IdType="pmc">PMC6343620</ArticleId><ArticleId IdType="pubmed">30118386</ArticleId></ArticleIdList></Reference><Reference><Citation>See I., Lale A., Marquez P., Streiff M.B., Wheeler A.P., Tepper N.K., Woo E.J., Broder K.R., Edwards K.M., Gallego R., et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann. Intern. Med. 2022;175:513–522. doi: 10.7326/M21-4502.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4502</ArticleId><ArticleId IdType="pmc">PMC8787833</ArticleId><ArticleId IdType="pubmed">35038274</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration  Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Guidance for Industry. September 2007.  [(accessed on 1 February 2021)]; Available online:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical.</Citation></Reference><Reference><Citation>Sadoff J., Le Gars M., Shukarev G., Heerwegh D., Truyers C., de Groot A.M., Stoop J., Tete S., Van Damme W., Leroux-Roels I., et al. Interim results of a Phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N. Engl. J. Med. 2021;384:1824–1835. doi: 10.1056/NEJMoa2034201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034201</ArticleId><ArticleId IdType="pmc">PMC7821985</ArticleId><ArticleId IdType="pubmed">33440088</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gars M., Sadoff J., Struyf F., Heerwegh D., Truyers C., Hendriks J., Gray G., Grinsztejn B., Goepfert P.A., Schuitemaker H., et al. Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. J. Infect. Dis. 2022;226:979–982. doi: 10.1093/infdis/jiac142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac142</ArticleId><ArticleId IdType="pmc">PMC9047246</ArticleId><ArticleId IdType="pubmed">35429381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Buttery Monash J. Interim Case Definition of Thrombosis with Thrombocytopenia Syndrome (TTS) v10.16.4. Nov 11, 2021.  [(accessed on 22 October 2022)].  Available online:  https://brightoncollaboration.org/thrombosis-with-thrombocytopenia-syndrome-vaccine-induced-immune-thrombocytopenia-and-thrombosis/</Citation></Reference><Reference><Citation>Ouedraogo H.G., Zoure A.A., Compaore T.R., Ky H., Zida S., Zingue D., Ouedraogo O., Soubeiga S.T., Sagna T., Dabire C., et al. Evaluation of ten (10) SARS-CoV-2 rapid serological tests in comparison with WANTAI SARS-CoV-2 ab ELISA in Burkina Faso, West Africa. Virol. J. 2023;20:57. doi: 10.1186/s12985-023-02011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02011-4</ArticleId><ArticleId IdType="pmc">PMC10062271</ArticleId><ArticleId IdType="pubmed">36997951</ArticleId></ArticleIdList></Reference><Reference><Citation>Larese Filon F., Purpuri A., Camata D., Bovenzi M., Rui F., Ronchese F., De Michieli P., Marcello A., Poggianella M., Confalonieri M., et al. Low sensitivity of rapid tests detecting anti-CoV-2 IgG and IgM in health care workers’ serum for COVID-19 screening. Med. Lav. 2021;112:331–339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8600574</ArticleId><ArticleId IdType="pubmed">34726663</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., Stieh D.J., Sarnecki M., Walsh S.R., Tomaras G.D., Kublin J.G., McElrath M.J., Alter G., Ferrari G., Montefiori D., et al. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): A randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020;7:e688–e698. doi: 10.1016/S2352-3018(20)30229-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(20)30229-0</ArticleId><ArticleId IdType="pmc">PMC7529856</ArticleId><ArticleId IdType="pubmed">33010242</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry H., Mutua G., Kibuuka H., Anywaine Z., Sirima S.B., Meda N., Anzala O., Eholie S., Betard C., Richert L., et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021;18:e1003813. doi: 10.1371/journal.pmed.1003813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003813</ArticleId><ArticleId IdType="pmc">PMC8555783</ArticleId><ArticleId IdType="pubmed">34714820</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisch N.C., Stephenson K.E., Williams K., Cox F., van der Fits L., Heerwegh D., Truyers C., Habets M.N., Kanjilal D.G., Larocca R.A., et al. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. Ann. Intern. Med. 2021;174:585–594. doi: 10.7326/M20-5306.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5306</ArticleId><ArticleId IdType="pubmed">33587687</ArticleId></ArticleIdList></Reference><Reference><Citation>Anywaine Z., Barry H., Anzala O., Mutua G., Sirima S.B., Eholie S., Kibuuka H., Betard C., Richert L., Lacabaratz C., et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 2022;19:e1003865. doi: 10.1371/journal.pmed.1003865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003865</ArticleId><ArticleId IdType="pmc">PMC8752100</ArticleId><ArticleId IdType="pubmed">35015777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas V., Le Gars M., Truyers C., Ruiz-Guinazu J., Struyf F., Colfer A., Bonten M., Borobia A., Reisinger E.C., Kamerling I.M.C., et al. Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine. 2024;42:3536–3546. doi: 10.1016/j.vaccine.2024.04.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.04.059</ArticleId><ArticleId IdType="pubmed">38705804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31208-3</ArticleId><ArticleId IdType="pmc">PMC7255193</ArticleId><ArticleId IdType="pubmed">32450106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. doi: 10.1016/S0140-6736(20)31605-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31605-6</ArticleId><ArticleId IdType="pmc">PMC7836858</ArticleId><ArticleId IdType="pubmed">32702299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>